Claritev (CTEV) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
29 Apr, 2026Opening remarks and agenda
Meeting opened virtually to enable broader stockholder participation, with introductions of board members and independent auditor present.
Housekeeping details included meeting recording availability, rules, and procedures for submitting questions and voting.
Quorum confirmed, meeting officially convened, and polls for voting opened at 9:03 A.M. on April 29, 2026.
Board and executive committee updates
Four class three director nominees presented for election to serve until the 2029 annual meeting; no other nominations received.
Shareholder proposals
Four proposals presented: election of directors, ratification of PwC as auditor, advisory say-on-pay vote, and amendment to the 2020 Omnibus Incentive Plan.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Claritev
- Q1 2026 revenue grew 5.8% to $244.7M, with margin gains but continued net losses.CTEV
Q1 20267 May 2026 - 2026 guidance targets $980M–$1B revenue, 61–62% EBITDA margin, and AI-driven growth.CTEV
Investor Day 202629 Apr 2026 - Definitive additional proxy materials outline voting procedures for the upcoming meeting.CTEV
Proxy filing20 Mar 2026 - Board recommends all proxy proposals amid strong 2025 results and governance enhancements.CTEV
Proxy filing20 Mar 2026 - Record bookings, robust AI-driven growth, and disciplined investment fuel expansion.CTEV
Status update6 Mar 2026 - Revenue and EBITDA grew, losses narrowed, and 2026 outlook includes buybacks and expansion.CTEV
Q4 202523 Feb 2026 - Q2 2024 net loss was $576.7M on $233.5M revenue, driven by a $553.7M impairment.CTEV
Q2 20242 Feb 2026 - Q3 2024 net loss surged on a $361.6M impairment as revenue fell 5.1% year-over-year.CTEV
Q3 202416 Jan 2026 - Transformation, tech investment, and data-driven strategy fuel growth and innovation in healthcare.CTEV
44th Annual J.P. Morgan Healthcare Conference15 Jan 2026